The DOI matches its Crossref record.
SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumours
Abstract
Summary: objective Somatostatin receptor scintigraphy (SRS) of neuroendocrine (NE) tumours is often challenging because of minute lesion size and poor anatomic delineation. This study evaluates the impact of sequentially performed single‐photon emission computed tomography (SPECT)/CT fusion on SRS study interpretation and clinical management of these tumours. patients and design Seventy‐two patients were studied with routine SRS and SPECT/CT at 4, 24 and optionally 48 h after injection of 222 MBq 111 In‐pentetreotide. Forty‐five patients were evaluated for carcinoid, 15 for islet cell tumour, seven for metastatic NE tumour, four for medullary thyroid carcinoma, and one patient had ophthalmopathy. SPECT/CT induced improvement in the interpretation of SPECT and conventional CT and resultant clinical management changes were recorded. results SRS was negative in 28 patients and positive in 44 patients. SPECT/CT provided no additional information in 48 patients, including all 28 negative studies. SPECT/CT improved localization of the SPECT‐detected lesions in 23 of the 44 positive studies. It defined the extent of disease in 17, showed unsuspected bone involvement in three, and differentiated physiological from tumour uptake in three studies. SPECT/CT affected the clinical management in 10 patients, altered the surgical approach in six, spared unnecessary surgery in two, and modified the therapeutic modality in two patients. conclusions SPECT/CT affected the diagnostic interpretation of SRS in 32% of the patients and induced changes in management in 14% of the patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Jensen, R. T., Berna, M. J., Bingham, D. B., & Norton, J. A. (2008) · Cancer · doi:10.1002/cncr.23648 · Cited by 488
A review on the clinical uses of SPECT/CT
Mariani, G., Bruselli, L., Kuwert, T., Kim, E. E., Flotats, A., Israel, O., Dondi, M., & Watanabe, N. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1390-8 · Cited by 438
Self-citationImaging of Neuroendocrine Tumors
Rufini, V., Calcagni, M. L., & Baum, R. P. (2006) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2006.03.007 · Cited by 376
Metadata
- Authors
- Krausz, Y., Keidar, Z., Kogan, I., Even‐Sapir, E., Bar‐Shalom, R., Engel, A., Rubinstein, R., Sachs, J., Bocher, M., Agranovicz, S., Chisin, R., & Israel, O.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2003-10-23
- Volume
- 59
- Issue
- 5
- Pages
- 565-573
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2094375201
- Cited by
- 192
- References
- 0
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumours. https://app.cochat.ai/papers/10.1046/j.1365-2265.2003.01885.x
- The paper
- Krausz, Y., Keidar, Z., Kogan, I., Even‐Sapir, E., Bar‐Shalom, R., Engel, A., Rubinstein, R., Sachs, J., Bocher, M., Agranovicz, S., Chisin, R., & Israel, O. (2003). SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumours. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2003.01885.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.